Expression and clinical significance of undifferentiated embryonic cell transcription factor 1 in breast cancer.

Background: At present, due to the heterogeneity of breast cancer, common tumor markers have certain limitations in clinical prognostic evaluation. This suggests an unmet need for markers to predict clinical outcomes and potentially guide targeted therapies. The present study sought to explore the expression level and clinical significance of undifferentiated embryonic cell transcription factor 1 (UTF1) in breast cancer.

Estrogen receptor-negative/progesterone receptor-positive and her-2-negative breast cancer might no longer be classified as hormone receptor-positive breast cancer.

Background: The single progesterone receptor (PR)-positive phenotype (estrogen receptor (ER)-/PR + , sPR positive) is an infrequent and independent biological entity. However, the prognosis of patients with sPR-positive and her-2-negative phenotype is still controversial, and it is not always easy to decide treatment strategies for them.

Methods: Patients during 2010-2014 were identified from Surveillance, Epidemiology, and End Results (SEER) database.

How Young Is Too Young in Breast Cancer?-Young Breast Cancer Is Not a Unique Biological Subtype.

Background: There is no uniformly adopted cutoff value to define "young patients" with breast cancer. This study was designed to determine an optimal cutoff value, to investigate prognostic factors and to explore gene expression profiles of young female breast cancer.

Materials And Methods: The Surveillance, Epidemiology, and End Results database was examined to identify cases of female breast cancer diagnosed between 2000 and 2007.

Clinical Nomogram for Predicting Survival Outcomes in Early Mucinous Breast Cancer.

Background: The features related to the prognosis of patients with mucinous breast cancer (MBC) remain controversial. We aimed to explore the prognostic factors of MBC and develop a nomogram for predicting survival outcomes.

Methods: The Surveillance, Epidemiology, and End Results (SEER) database was searched to identify 139611 women with resectable breast cancer from 1990 to 2007.

[Efficacy of neoadjuvant chemotherapy with FEC and TEC regimen on breast cancer].

Background And Objective: Neoadjuvant chemotherapy can remarkably decrease tumor size and stage, and improve the efficacy of comprehensive treatment on breast carcinoma. This study was to investigate the efficacy of neoadjuvant chemotherapy with FEC and TEC regimen on breast cancer.

Methods: From April 1998 to April 2004, 112 breast cancer patients were treated with neoadjuvant chemotherapy.